Streetbeat News

Stock Prices

NSP

Insperity has released its Q3 outlook, projecting adjusted EPS between $0.21 and $0.45, which is below the estimated $0.54. The GAAP EPS is expected to range from $(0.11) to $0.13.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:09 pm

SHIBUSD

Shiba Inu (SHIB) celebrates its fourth birthday with a 936% spike in its burn rate, removing 8.1 million SHIB from circulation in the past 24 hours. The marketing lead emphasized long-term development amid market volatility.

Portfolio Pulse from Khyathi Dalal

August 01, 2024 | 12:09 pm

CRAI

Charles River Associates (CRAI) has raised its FY24 revenue outlook from the previous range of $645M - $675M to a new range of $670M - $685M, surpassing the estimated $667.608M.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:08 pm

BBIO

BridgeBio Pharma reported a Q2 2024 GAAP EPS of $(0.39), beating the estimate of $(1.06). However, the company's sales of $2.168 million missed the estimate of $3.569 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:07 pm

NSP

Insperity has raised its FY24 outlook, adjusting its EPS guidance. The company now expects adjusted EPS to be between $3.33 and $3.88, compared to the previous range of $3.17 to $3.90 and the consensus estimate of $3.65. GAAP EPS guidance has been revised to $2.18 to $2.73, up from $2.02 to $2.75, against the consensus estimate of $2.59.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:07 pm

LIPO

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced a $1.28 million registered direct offering of 2,066,000 shares of common stock at $0.62 per share. The offering is expected to close on August 1, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:07 pm

GWW

W.W. Grainger has updated its 2024 guidance, narrowing its earnings per share (EPS) outlook to $38.00-$39.50 from the previous $38.00-$40.50, and its revenue forecast to $17.0-$17.3 billion from the prior $17.2-$17.7 billion. The company also adjusted other financial metrics, including sales growth, operating margin, and share buyback plans.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

CRAI

CRA Intl (NASDAQ:CRAI) reported Q2 2024 adjusted EPS of $1.83, beating the $1.50 estimate by 22%. Sales were $171.442M, surpassing the $168.253M estimate by 1.90%. This represents a 28.87% increase in EPS and a 5.85% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

AY

Atlantica Sustainable reported Q2 2024 GAAP EPS of $0.18, missing the $0.36 estimate. However, sales were $328.262M, beating the $326.447M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

MRK

Daiichi Sankyo and Merck have announced the dosing of the first patient in the Phase 3 IDeate-Lung02 trial. This trial is evaluating Ifinatamab Deruxtecan for relapsed small cell lung cancer compared to chemotherapy.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:05 pm